Literature DB >> 25790523

Utility of M30, an apoptotic serum marker, in liver diseases.

Akif Altinbaş, Şahin Çoban, Ömer Başar, Osman Yüksel.   

Abstract

The aim of this paper is to evaluate the role of apoptosis in some common liver diseases, and the utility of M30, an apoptotic serum marker, in the diagnosis of the severity of underlying hepatic injury. As is widely known, apoptosis is programmed cell death, and its deregulation results in an uncontrolled inflammatory process leading to upregulation of liver fibrogenesis. Both extrinsic and intrinsic pathways are crucial in apoptosis, and caspase cleavage of cytokeratin proteins occurs in both. Therefore, the measurement of caspase- cleaved cytokeratin fragments could be a novel method to assess the intensity of apoptotic cell numbers in epithelial tissue damage. M30 levels were found to increase not only in acute liver disorders, but also in some chronic liver injuries. We tried to summarize the recent studies focused on the role of apoptotic processes in liver diseases, mainly those that investigated the use of M30 in determining the severity of, or in predicting, ongoing liver injury.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25790523     DOI: 10.3906/sag-1309-14

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  2 in total

1.  The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients.

Authors:  Baris Yilmaz; Bora Aktas; Akif Altinbas; Zeynep Ginis; Gulfer Ozturk; Fuat Ekiz; Serta Kilincalp; Murat Deveci; Zahide Simsek; Sahin Coban; Omer Basar; Osman Yuksel
Journal:  Hepat Mon       Date:  2016-08-10       Impact factor: 0.660

2.  Serum Caspase-Cleaved Cytokeratin (M30) Indicates Severity of Liver Dysfunction and Predicts Liver Outcome.

Authors:  Hani Oweira; Mahmoud Sadeghi; Daniel Volker; Markus Mieth; Ahmed Zidan; Elias Khajeh; Omid Ghamarnejad; Hamidreza Fonouni; Karl Heinz Weiss; Jan Schmidt; Imad Lahdou; Arianeb Mehrabi
Journal:  Ann Transplant       Date:  2018-06-08       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.